Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• BonadonnaGBonfanteVVivianiSDi RussoAVillaniFValagussaPABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term resultsJ Clin Oncol200422142835284115199092
   PubMed Web of Science ®Google Scholar
• EngertADiehlVFranklinJEscalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 studyJ Clin Oncol200927274548455419704068
   PubMed Web of Science ®Google Scholar
• QuddusFArmitageJOSalvage therapy for Hodgkin’s lymphomaCancer J200915216116319390313
   PubMed Web of Science ®Google Scholar
• MajhailNSWeisdorfDJDeforTELong-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphomaBiol Blood Marrow Transplant200612101065107217084370
   PubMed Web of Science ®Google Scholar
• CrumpMManagement of Hodgkin lymphoma in relapse after autologous stem cell transplantASH Education Program Book200820081326333
   Google Scholar
• KewalramaniTNimerSDZelenetzADProgressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphomaBone Marrow Transplant200332767367913130314
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th edGeneva, SwitzerlandWorld Health Organization Press20082
   Google Scholar
• FaliniBPileriSPizzoloGCD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapyBlood19958511147803786
   PubMed Web of Science ®Google Scholar
• AizawaSNakanoHIshidaTTumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activationJ Biol Chem19972724204220458999898
   PubMed Web of Science ®Google Scholar
• BartlettNLYounesACarabasiMHA phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesBlood200811141848185418079362
   PubMed Web of Science ®Google Scholar
• Forero-TorresALeonardJPYounesAA Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaBr J Haematol2009146217117919466965
   PubMed Web of Science ®Google Scholar
• SieversELSenterPDAntibody-drug conjugates in cancer therapyAnnu Rev Med201364152923043493
   PubMed Web of Science ®Google Scholar
• FanaleMAForero-TorresARosenblattJDA phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignanciesClin Cancer Res201218124825522080439
   PubMed Web of Science ®Google Scholar
• YounesAGopalAKSmithSEResults of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphomaJ Clin Oncol201230182183218922454421
   PubMed Web of Science ®Google Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• GopalAKRamchandrenRO’ConnorOASafety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationBlood2012120356056822510871
   PubMed Web of Science ®Google Scholar
• EvensAMFenskeTSHamlinPPancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventBlood2013122214380
   Web of Science ®Google Scholar
• Wagner-JohnstonNDBartlettNLCashenABergerJRProgressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotinLeuk Lymphoma201253112283228622424602
   PubMed Web of Science ®Google Scholar
• City of Hope Medical CenterBrentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin LymphomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated December 19, 2013]. Available from http://clinicaltrials.gov/show/NCT01393717. NLM identifier: NCT01393717Accessed January 31, 2014
   Google Scholar
• Memorial Sloan-Kettering Cancer CenterBrentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin LymphomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated October 16, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01508312?term=NCT01508312&rank=1. NLM identifier: NCT01508312Accessed January 31, 2014
   Google Scholar
• Seattle Genetics, IncA Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated January 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01100502?term=NCT01100502&rank=1. NLM identifier: NCT01100502Accessed January 31, 2014
   Google Scholar
• Millennium Pharmaceuticals, IncPhase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin LymphomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2014 [updated January 6, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01712490?term=NCT01712490&rank=1. NLM identifier: NCT01712490Accessed January 31, 2014
   Google Scholar
• YounesAConnorsJMParkSIBrentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation studyLancet Oncol201314131348135624239220
   PubMed Web of Science ®Google Scholar
• Seattle Genetics, IncA Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated December 20, 2013]. Available from http://clinicaltrials.gov/show/NCT01716806. NLM identifier: NCT01716806Accessed January 31, 2014
   Google Scholar
• ChenRPalmerJMThomasSHBrentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphomaBlood2012119266379638122611160
   PubMed Web of Science ®Google Scholar
• ChenRFormanSJPalmerJTwo-year follow-up of patients with relapsed/refractory Hodgkin treated with brentuximab vedotin prior to reduced intensity allogeneic hematopoietic cell transplantationPresented at the 12th International Conference on Malignant LymphomaLugano, SwitzerlandJune 19–22, 2013
   Google Scholar
• ChenRWPalmerJSiddiqiTBrentuximab vedotin as first line salvage therapy in relapsed/refractory HLASH Annual Meeting Abstracts2012120213699
   Google Scholar
• MoskowitzAJSchoderHGerecitanoJPET-adapted sequential therapy with brentuximab vedotin and augmented-ICE induces FDG-PET normalization in 92% of patients with relapsed and refractory Hodgkin lymphomaPresented at the 12th International Conference on Malignant LymphomaLugano, SwitzerlandJune 19–22, 2013
   Google Scholar
• GoyalSDBartlettNLWhere does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?Curr Hematol Malig Rep20127317918522669711
   PubMed Web of Science ®Google Scholar
• BartlettNBricePChenRWRetreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II studyASCO Meeting Abstracts201230Suppl 158027
   Google Scholar
• Forero-TorresABerrymanRBAdvaniRHProlonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)ASH Annual Meeting Abstracts2011118213711
   Google Scholar